- Home
- NREF vs CRDF Comparison
NREF vs CRDF Comparison
Compare NREF & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NREF
- CRDF
- Stock Information
- Founded
- NREF 2019
- CRDF 1999
- Country
- NREF United States
- CRDF United States
- Employees
- NREF N/A
- CRDF 33
- Industry
- NREF Real Estate Investment Trusts
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NREF Real Estate
- CRDF Health Care
- Exchange
- NREF Nasdaq
- CRDF Nasdaq
- Market Cap
- NREF 244.3M
- CRDF 233.5M
- IPO Year
- NREF 2020
- CRDF N/A
- Fundamental
- Price
- NREF $13.88
- CRDF $4.10
- Analyst Decision
- NREF Hold
- CRDF Strong Buy
- Analyst Count
- NREF 3
- CRDF 6
- Target Price
- NREF $14.50
- CRDF $11.92
- AVG Volume (30 Days)
- NREF 72.1K
- CRDF 1.5M
- Earning Date
- NREF 07-31-2025
- CRDF 08-07-2025
- Dividend Yield
- NREF 14.44%
- CRDF N/A
- EPS Growth
- NREF N/A
- CRDF N/A
- EPS
- NREF 2.59
- CRDF N/A
- Revenue
- NREF $110,996,000.00
- CRDF $587,000.00
- Revenue This Year
- NREF $25.18
- CRDF N/A
- Revenue Next Year
- NREF $3.65
- CRDF N/A
- P/E Ratio
- NREF $5.35
- CRDF N/A
- Revenue Growth
- NREF 370.78
- CRDF N/A
- 52 Week Low
- NREF $12.14
- CRDF $2.01
- 52 Week High
- NREF $18.09
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- NREF 46.24
- CRDF 66.57
- Support Level
- NREF $13.54
- CRDF $3.07
- Resistance Level
- NREF $14.01
- CRDF $3.24
- Average True Range (ATR)
- NREF 0.38
- CRDF 0.23
- MACD
- NREF 0.01
- CRDF 0.06
- Stochastic Oscillator
- NREF 61.71
- CRDF 92.98
About NREF NexPoint Real Estate Finance Inc.
NexPoint Real Estate Finance Inc is a real estate investment trust. The company provides structured financing solutions by investing in mid-sized multifamily, storage and select-service, and extended-stay hospitality properties. Its investment objective is to generate attractive, risk-adjusted returns for stockholders over the long term. The Company is focused on originating, structuring and investing in first-lien mortgage loans, mezzanine loans, preferred equity, convertible notes, multifamily properties, and common equity investments, as well as multi-family and single-family rental ("SFR") commercial mortgage-backed securities securitizations ("CMBS securitizations"), multifamily structured credit risk notes ("MSCR Notes") and mortgage-backed securities.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.